Stock TOBIRA THERAPEUTICS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Tobira Therapeutics Inc

Equities

US88883P1012

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Tobira Therapeutics Inc

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Tobira Therapeutics : Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting
BU
Tobira Therapeutics : Announces Presentations Related to Cenicriviroc’s Development Program in NASH at the American Academy for the Study of Liver Diseases Annual Meeting
BU
TBRA Brower Piven Commences An Investigation Into The Proposed Sale Of Tobira Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
BU
Tobira Therapeutics : Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Position in NASH
PU
Tobira Therapeutics : Announces Initiation of Phase 1 Combination Study of Cenicriviroc and Evogliptin
BU
Tobira Therapeutics : Announces Appointment of Dr. Laurent Fischer as Industry Co-chair of the Liver Forum Steering Committee
BU
Tobira Therapeutics : to Participate in Two Conferences in September
BU
Tobira Therapeutics : Reports Second Quarter 2016 Financial and Business Results
BU
Tobira Therapeutics : to Present at the 36th Annual Canaccord Genuity Growth Conference
BU
Tobira Therapeutics Announces Date of 2016 Second Quarter Financial Results and CENTAUR Study Update Conference Call
GL
Tobira Therapeutics : Announces Clinically and Statistically Significant Improvement in Liver Fibrosis From Phase 2b CENTAUR NASH Trial at One Year
BU
Tobira Therapeutics to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss CENTAUR Phase 2b Trial Results
BU
Tobira Therapeutics : Cenicriviroc Reduces Inflammation and Fibrosis in Animal Models of Chronic Liver and Kidney Disease Including NASH
PU
Tobira Therapeutics : Cenicriviroc Reduces Inflammation and Fibrosis in Animal Models of Chronic Liver and Kidney Disease Including NASH
BU
Tobira Therapeutics : Cenicriviroc Shown to Reduce Liver Injury in Independent Research Published in the Journal Hepatology
PU
Tobira Therapeutics : Cenicriviroc Shown to Reduce Liver Injury in Independent Research Published in the Journal Hepatology
BU
Tobira Therapeutics Announces Date of 2016 First Quarter Financial Results and Conference Call
GL
Tobira Therapeutics Announces Date of 2015 Fourth Quarter Financial Results and Conference Call
GL
Tobira Therapeutics : to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
PU
Tobira Therapeutics : Completes Financing and Merger with Regado Biosciences
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Tobira Therapeutics Inc